This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Renwick MJ, Smolina K, Gladstone EJ, Weymann D, Morgan SG. Postmarket policy considerations for biosimilar oncology drugs. Lancet Oncol. 2016;17:e31–8.
Daller J. Biosimilars: A consideration of the regulations in the United States and European union. Regul Toxicol Pharm. 2016;76:199–208.
Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187–205.
Cottler-Fox MH, Lapidot T, Petit I, Kollet O, DiPersio JF, Link D, et al. Stem cell mobilization. Hematology Am Soc Hematol Educ Program. 2003:419–37.
Waller CF, Semiglazov VF, Tjulandin S, Bentsion D, Chan S, Challand R. A phase III randomized equivalence study of biosimilar filgrastim versus Amgen filgrastim in patients receiving myelosuppressive chemotherapy for breast cancer. Onkologie 2010;33:504–11.
Shaw BE, Confer DL, Hwang WY, Pamphilon DH, Pulsipher MA. Concerns about the use of biosimilar granulocyte colony-stimulating factors for the mobilization of stem cells in normal donors: position of the World Marrow Donor Association. Haematologica 2011;96:942–7.
Elayan MM, Horowitz JG, Magraner JM, Shaughnessy PJ, Bachier C. Tbo-Filgrastim versus Filgrastim during Mobilization and Neutrophil Engraftment for Autologous Stem Cell Transplantation. Biol Blood Marrow Transpl. 2015;21:1921–5.
Bassi S, Stroppa EM, Moroni CF, Arbasi MC, Trabacchi E, Di Franco A, et al. Safety and efficacy of granulocyte colony-stimulating factor biosimilars in engraftment after autologous stem cell transplantation for haematological malignancies: a 4-year, single institute experience with different conditioning regimens. Blood Transfus. 2015;13:478–83.
Marchesi F, Cerchiara E, Dessanti ML, Gumenyuk S, Franceschini L, Palombi F, et al. Comparison between biosimilar filgrastim vs other granulocyte-colony stimulating factor formulations (originator filgrastim, peg-filgrastim and lenograstim) after autologous stem cell transplantation: a retrospective survey from the Rome Transplant Network. Br J Haematol. 2015;169:293–6.
Ianotto JC, Tempescul A, Yan X, Delepine P, Le Calloch R, Hardy E, et al. Experience (1 year) of G-CSF biosimilars in PBSCT for lymphoma and myeloma patients. Bone Marrow Transpl. 2012;47:874–6.
Gascon P. Presently available biosimilars in hematology-oncology: G-CSF. Target Oncol 2012;7:S29–34.
Italian Medicines Agency. The Medicines Utilisation Monitoring Centre (OsMed). National report on medicines use in Italy. Year 2015. Rome: OsMed; 2016, p. 566.
Acknowledgements
This work was supported by Fondi di Ricerca Locale, Università degli Studi di Torino, Torino, Italy and by Fondazione Neoplasie del sangue (FO.NE. SA),Torino, Italy. The authors would like to thank Maria Josè Fornaro, Antonella Fiorillo and Franca Trotto Gatta for excellent secretarial support.
Author information
Authors and Affiliations
Contributions
L.G., M.B., and B.B. designed the study. L.G. and B.B. wrote the report. B.B. supervised the clinical conduction of the study and data analysis. L.B. collected data. B.B., L.G., L.B., M.M., D.F., F.C., G.L., and S.B. recruited the patients and supervised data collection. M.S. and F.C. provided cost analysis. T.F., P.O., V.R., and V.T. provided stem cell collection, mobilization data. M.B., M.M., J.S.L., S.L., B.B., and L.G., and reviewed and assisted in writing the manuscript. A.E. did the statistical analysis.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Giaccone, L., Brunello, L., Londono, J.S. et al. Cost efficiency and effectiveness of biosimilar filgrastim in autologous transplant. Bone Marrow Transplant 57, 312–314 (2022). https://doi.org/10.1038/s41409-021-01541-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41409-021-01541-1